Results of observational post-registration study of the efficacy and safety of Trekrezan® medicine use in adult patients with acute respiratory viral infection

The widespread prevalence of respiratory viruses, their genetic variability, which leads to the occurence of completely new viruses, such as SARS-CoV-2, determines the need to expand the range of drugs with both direct and indirect antiviral influence. Adaptogen with an immunomodulatory effect Trekrezan® (LLC Grotex, Russia) could be referred to such kind of medicines. The aim of the study was to study the efficacy and safety of Trekrezan® in ARVI treatment in adults. Material and methods. 130 patients with ARVI at the age of 18-60 years were examined. The main group included 100 patients who received Trekrezan® 200 mg according to the following scheme: on the first day - 1 tablet 3 times/day (600 mg), in the next 7 days - 1 tablet 1 time/day (200 mg). The control group included 30 patients who received symptomatic therapy, when it was necessary. The efficacy of Trekrezan® was estimated depending on the dynamics of body temperature and other clinical symptoms normalization, improvement of laboratory parameters, and the frequency of complications. Its safety was assessed by the presence or absence of adverse events, as well as the influence of the medicine on vital functions of the organism. Results. It has been shown that the use of Trekrezan® leads to a significantly faster (on average 2,2 days) elimination of the clinical manifestations of acute respiratory viral infections due to a relieve of fever, decrease of the severity of intoxication syndrome symptoms, normalization of general clinical and biochemical blood parameters (ESR, leukocyte count and CRP) comparatively with the control group. Complications of ARVI while taking the medicine were not fixed. Adverse events in the study groups were not registered, which indicates the safety of medicine use. Conclusion. Trekrezan® has proven its effectiveness and safety in the current study, which allows us to recommend it for ARVI treatment in adult patients.

acute respiratory viral infections, antiviral therapy, Trekrezan